221 related articles for article (PubMed ID: 33208919)
61. KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer.
Renaud S; Romain B; Falcoz PE; Olland A; Santelmo N; Brigand C; Rohr S; Guenot D; Massard G
Br J Cancer; 2015 Feb; 112(4):720-8. PubMed ID: 25688918
[TBL] [Abstract][Full Text] [Related]
62. Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability.
Nazemalhosseini-Mojarad E; Kishani Farahani R; Mehrizi M; Baghaei K; Yaghoob Taleghani M; Golmohammadi M; Peyravian N; Ashtari S; Pourhoseingholi MA; Asadzadeh Aghdaei H; Zali MR
J Gastrointest Cancer; 2020 Mar; 51(1):53-62. PubMed ID: 30635874
[TBL] [Abstract][Full Text] [Related]
63. Molecular characteristics of early-onset compared with late-onset colorectal cancer: A case controlled study.
Tang J; Peng W; Tian C; Zhang Y; Ji D; Wang L; Jin K; Wang F; Shao Y; Wang X; Sun Y
Int J Surg; 2024 May; ():. PubMed ID: 38742845
[TBL] [Abstract][Full Text] [Related]
64. The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients.
Won DD; Lee JI; Lee IK; Oh ST; Jung ES; Lee SH
BMC Cancer; 2017 Jun; 17(1):403. PubMed ID: 28583095
[TBL] [Abstract][Full Text] [Related]
65. The RAS mutation status predicts survival in patients undergoing hepatic resection for colorectal liver metastases: The results from a genetic analysis of all-RAS.
Amikura K; Akagi K; Ogura T; Takahashi A; Sakamoto H
J Surg Oncol; 2018 Mar; 117(4):745-755. PubMed ID: 29194647
[TBL] [Abstract][Full Text] [Related]
66. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
Bokemeyer C; Bondarenko I; Hartmann JT; de Braud F; Schuch G; Zubel A; Celik I; Schlichting M; Koralewski P
Ann Oncol; 2011 Jul; 22(7):1535-1546. PubMed ID: 21228335
[TBL] [Abstract][Full Text] [Related]
67. Prognostic Factors Change Over Time After Hepatectomy for Colorectal Liver Metastases: A Multi-institutional, International Analysis of 1099 Patients.
Margonis GA; Buettner S; Andreatos N; Wagner D; Sasaki K; Barbon C; Beer A; Kamphues C; Løes IM; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Mischinger HJ; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
Ann Surg; 2019 Jun; 269(6):1129-1137. PubMed ID: 31082912
[TBL] [Abstract][Full Text] [Related]
68. Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations.
Ogura T; Kakuta M; Yatsuoka T; Nishimura Y; Sakamoto H; Yamaguchi K; Tanabe M; Tanaka Y; Akagi K
Oncol Rep; 2014 Jul; 32(1):50-6. PubMed ID: 24806883
[TBL] [Abstract][Full Text] [Related]
69. Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics.
Khan M; Loree JM; Advani SM; Ning J; Li W; Pereira AAL; Lam M; Raghav K; Morris VK; Broaddus R; Maru D; Overman MJ; Kopetz S
Clin Colorectal Cancer; 2018 Dec; 17(4):e699-e709. PubMed ID: 30205948
[TBL] [Abstract][Full Text] [Related]
70. Embryonic origin of primary colon cancer predicts survival in patients undergoing ablation for colorectal liver metastases.
Yamashita S; Odisio BC; Huang SY; Kopetz SE; Ahrar K; Chun YS; Conrad C; Aloia TA; Gupta S; Harmoush S; Hicks ME; Vauthey JN
Eur J Surg Oncol; 2017 Jun; 43(6):1040-1049. PubMed ID: 28187878
[TBL] [Abstract][Full Text] [Related]
71. Effect of Co-mutation of RAS and TP53 on Postoperative ctDNA Detection and Early Recurrence after Hepatectomy for Colorectal Liver Metastases.
Nishioka Y; Chun YS; Overman MJ; Cao HST; Tzeng CD; Mason MC; Kopetz SW; Bauer TW; Vauthey JN; Newhook TE;
J Am Coll Surg; 2022 Apr; 234(4):474-483. PubMed ID: 35290266
[TBL] [Abstract][Full Text] [Related]
72. Gene mutation and surgical technique: Suggestion or more?
Kawaguchi Y; Lillemoe HA; Vauthey JN
Surg Oncol; 2020 Jun; 33():210-215. PubMed ID: 31351766
[TBL] [Abstract][Full Text] [Related]
73. Impact of Age of Onset on Survival after Hepatectomy for Patients with Colorectal Cancer Liver Metastasis: A Real-World Single-Center Experience.
Wang HW; Wang LJ; Jin KM; Bao Q; Li J; Ge SK; Wang K; Xing BC
Curr Oncol; 2022 Nov; 29(11):8456-8467. PubMed ID: 36354726
[TBL] [Abstract][Full Text] [Related]
74. Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial.
Hegewisch-Becker S; Nöpel-Dünnebacke S; Hinke A; Graeven U; Reinacher-Schick A; Hertel J; Lerchenmüller CA; Killing B; Depenbusch R; Al-Batran SE; Lange T; Dietrich G; Tannapfel A; Arnold D
Eur J Cancer; 2018 Sep; 101():105-113. PubMed ID: 30036739
[TBL] [Abstract][Full Text] [Related]
75. KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma.
Siyar Ekinci A; Demirci U; Cakmak Oksuzoglu B; Ozturk A; Esbah O; Ozatli T; Celik B; Budakoglu B; Turker I; Bal O; Turan N
J BUON; 2015; 20(1):128-35. PubMed ID: 25778307
[TBL] [Abstract][Full Text] [Related]
76. Colorectal Liver Micrometastases: Association with RAS/TP53 Co-Mutation and Prognosis after Surgery.
Chun YS; Passot G; Nishioka Y; Katkhuda R; Arvide EM; Benzerdjeb N; Lopez J; Kopetz SE; Maru DM; Vauthey JN
J Am Coll Surg; 2022 Jul; 235(1):8-16. PubMed ID: 35703957
[TBL] [Abstract][Full Text] [Related]
77. Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for
Tang W; Ren L; Liu T; Ye Q; Wei Y; He G; Lin Q; Wang X; Wang M; Liang F; Cui Y; Xu J
J Clin Oncol; 2020 Sep; 38(27):3175-3184. PubMed ID: 32749938
[TBL] [Abstract][Full Text] [Related]
78. Is complete liver resection without resection of synchronous lung metastases justified?
Mise Y; Kopetz S; Mehran RJ; Aloia TA; Conrad C; Brudvik KW; Taggart MW; Vauthey JN
Ann Surg Oncol; 2015 May; 22(5):1585-92. PubMed ID: 25373535
[TBL] [Abstract][Full Text] [Related]
79. Impact of Single-organ Metastasis to the Liver or Lung and Genetic Mutation Status on Prognosis in Stage IV Colorectal Cancer.
Cavallaro P; Bordeianou L; Stafford C; Clark J; Berger D; Cusack J; Kunitake H; Francone T; Ricciardi R
Clin Colorectal Cancer; 2020 Mar; 19(1):e8-e17. PubMed ID: 31899147
[TBL] [Abstract][Full Text] [Related]
80. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
Stintzing S; Miller-Phillips L; Modest DP; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V;
Eur J Cancer; 2017 Jul; 79():50-60. PubMed ID: 28463756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
